Clinical Trial Update: Preoperative Imatinib Mesylate Combined With Rectal-sparing Surgery in Patients With c-KIT Gene-mutant Rectal GIST [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating preoperative Imatinib mesylate with rectal-sparing surgery for rectal GIST with c-KIT mutations; status not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor of Rectum

Drugs mentioned

• Imatinib mesylate (Imatinib)

Snippet

Sponsor: Fujian Medical University Union Hospital | Conditions: Gastrointestinal Stromal Tumor of Rectum | Phase 3 | Status: NOT_YET_RECRUITING